THE EXPERIMENTAL MODEL OF AUTOIMMUNE PROCESS: THE ROLE OF EPIGENETIC VARIATION IN THE POPULATION OF MICE HYBRIDS

Cover Page

Abstract


Background: At the development of graft versus host disease in genetically homogeneous population of (C57Bl/6 x DBA/2) F1 mice two clinical phenotypes of SLE-like disease were revealed: lupus+ (immune complex glomerulonephritis and hemolytic anemia) and lupus – (hemolytic anemia). The GvHD phenotypic heterogeneity is determined by the Th1 /Th2-polarization: Th2 lymphocyte predominant activity, leads to the lupus+ development, or prevalence activity of Th1 cells, leads to the lupus– development. Objective: Our aim was to evaluate the possibility of using an experimental model of autoimmune disease for studying and testing of epigenetic modifications, shifting Th1 /Th2-
balance in vivo. Methods: Сhronic GVHD was induced in B6D2F1 mice by the transplantation of 130×10 6 parental DBA/2 splenocytes. Аnti-ds-DNA, total IgG and IgG1, IgG2а Abs were measured by ELISA. Results: Six- to 8-week-old female DBA/2 and B6D2F1 mice were obtained from Biological Research Laboratory (Novosibirsk). It was established that regular moderate physical activity (unladed swimming) shifted Th1 /Th2 balance towards Th1. This leads to a decrease in a population of recipients the lupus+ mice from 57 to 26% (p <0,001) with significantly reduced hypergammaglobulinemia (IgG from 2,8 to 2,0 mg/ml; p <0,047) and DNA antibodies titer from 0,18 to 0,12 OD (p =0,05). Administration of epigenetic modificator bisphenol A at low doses, which mimicking estrogen effects, enhances the proportion of lupus+ mice in experimental groups from 33 to 64% (p <0,001) and impairs their clinical status by the increasing the urine protein level from 2.8 to 4,2 mg/ml (p <0,001) in animals. Conclusion: Th1 /Th2 – balance presumably is determined by the immune system epigenetic modification in experimental mice, formed on the previous stages of ontogeny and defines the direction of immune processes development in individual animal.



O. P. Kolesnikova

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Author for correspondence.
Email: iscreen2001@mail.ru

Russian Federation

доктор медицинских наук, руководитель лаборатории экспериментальной иммуноте-
рапии НИИ фундаментальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-06-72

O. T. Kudaeva

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: iscreen2001@mail.ru

Russian Federation

доктор биологических наук, ведущий научный сотрудник лаборатории эксперимен-
тальной иммунотерапии НИИ фундаментальной и клинической иммунологии

N. N. Vol'skii

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: dtheory@yandex.ru

Russian Federation

кандидат медицинских наук, ведущий научный сотрудник лаборатории эксперимен-
тальной иммунотерапии НИИ фундаментальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-06-72

E. V. Goiman

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: l.goiman@mail.ru

Russian Federation

кандидат медицинских наук, научный сотрудник лаборатории экспериментальной
иммунотерапии НИИ фундаментальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-06-72

E. D. Gavrilova

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: edav.gavr@mail.ru

Russian Federation

кандидат биологических наук, старший научный сотрудник лаборатории эксперимен-
тальной иммунотерапии НИИ фундаментальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-06-72

O. M. Perminova

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: pom.57@yandex.com

Russian Federation

кандидат медицинских наук, научный сотрудник лаборатории экспериментальной
иммунотерапии НИИ фундаментальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-06-72

E. N. Demchenko

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: elena.demchenko@gmail.ru

Russian Federation

кандидат химических наук, научный сотрудник лаборатории экспериментальной
иммунотерапии НИИ фундаментальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-06-72

V. A. Kozlov

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

Email: vakoz40@yandex.ru

Russian Federation

доктор медицинских наук, профессор, академик РАН, директор НИИ фундамен-
тальной и клинической иммунологии
Адрес: 630099, Новосибирск, ул. Ядринцевская, д. 14, тел.: +7 (383) 222-26-74

  1. Eisenberg R., Via C. T cells, murine chronic graft-versus-host disease and autoimmunity. J. Autoimmun. 2012; 39: 240–247.
  2. Cher D., Mosmann T. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J. Immunol. 1987; 138: 3688–3694.
  3. Szyf M. Epigenetic therapeutics in autoimmune disease. Clin. Rev. Allerg. Immunol. 2010; 39 (1): 62–77.
  4. van Panhuys N., Le Gros G., McConnell J. Epigenetic regulation of Th2 cytokine expression in atopic diseases. Tissue Antigens. 2008; 72 (2): 91–97.
  5. Sanders V., Epigenetic regulation of Th1 and Th2 cell development. Brain Behav. Immun. 2006; 20: 317–324.
  6. Via C., Shearer G. T cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol. Today. 1988; 9: 207–213.
  7. 7. Anway M., Cupp A.S, Uzumcu M., Skinner M. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005; 308: 1466–1469.
  8. Kimura M., Gleichmann E. Depressed antibody responses to exogenous antigens in mice with lupus-like graft-versus-host disease. Clin. Immunol. Immunopathol. 1987; 43 (1): 97–109.
  9. Kolesnikova O.P., Kudaeva O.T., Loginov V.A., Robinson M.V., Kolesnikova S.M., Kozlov V.A. Indicators immunopoiesis erythro- and development of autoimmune diseases induced by chronic graft versus host disease. Vestnik AMN SSSR = Bulletin of AcademyMedical Sciences of the USSR. 1991;12:13–16.
  10. Gerlinskaya L.A., Moshkin M.P., Evsikov V.I. Methodical aspects of determining the level of stress in wild animals. Ekologiya = Ecology. 1993;1:97–100.
  11. Muracami M., Yoshioka H., Shirai T., Tsubata T., Honjo T. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int. Immunol. 1995; 7 (5): 877–882.
  12. Nikolic B., Lee S., Bronson R.T, Grusby M., Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J. Clin. Invest. 2000; 105: 1289–1298.
  13. Morris S., Madden K., Adamovicz J., Gause W., Hubbard B., Gately M., Finkelman F. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol. 1994; 152: 1047–1056.
  14. Sukhenko T.G., Kolesnikova O.P., Filimonov P.N., Kozlov V.A. Status immuno- and erythropoiesis in mice with graft versus host disease in the immunocompromised. ZhMEI = Journal of microbiology, epidemiology and immunobiology. 1999; 4: 56–60.
  15. Reiss A.B., Awadallah N.W., Malhotra S., Montesinos M.C., Chan E.S., Javitt N.B., Cronstein B.N. Immune complexes and IFN-g decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J. Lipid Res. 2001; 42: 1913–1922.
  16. Chan R., Jiang P., Peng X., Tam L-S., Liao G., Li E. et al. Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc. Natl. Acad. Sci USA. 2014; 111 (49): 5302–5311.
  17. Whitacre C. Sex differences in autoimmune disease. Nat. Immunol. 2001; 2: 777–780.
  18. Waiserman A. Early-life exposure to endocrine disrupting chemicals and later-life health outcomes: an epigenetic bridge? Ading Dis. 2014; 5 (6): 419–429.

Views

Abstract - 66

PDF (Russian) - 27

Cited-By


PlumX

Dimensions

Comments on this article

View all comments


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies